REFERENCE
FDA.Early communication about an ongoing safety review aprotinin injection (marketed as Trasylol). Internet Document: [2 pages], 19 Oct 2007. Available from: URL: http://www.fda.gov
Rights and permissions
About this article
Cite this article
Interim analyses suggest that aprotinin is associated with an increased risk of death. React. Wkly. 1176, 2 (2007). https://doi.org/10.2165/00128415-200711760-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200711760-00004